An Open Label, Multi-Center, Randomized, Parallel Group Study Comparing the Efficacy and Safety of Insulin VIAject™ and Regular Human Insulin in Patients With Type 1 Diabetes Mellitus

NCT ID: NCT00542724

Last Updated: 2015-08-03

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 462 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2006-09-30

Brief Summary

The purpose of this study is to demonstrate equivalent blood glucose control in patients with type 1 diabetes mellitus with insulin VIAject™ and regular human insulin as prandial insulin and to demonstrate an equivalent safety profile for VIAject™ in comparison to regular human insulin.

Conditions

Type 1 Diabetes Mellitus

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

A

VIAject™

Group Type: EXPERIMENTAL

VIAject™

Intervention Type: DRUG

Dosage as individually required

B

Regular Human Insulin

Group Type: ACTIVE_COMPARATOR

Regular Human Insulin

Intervention Type: DRUG

Dosage as individually required

Interventions

VIAject™

Dosage as individually required

Intervention Type: DRUG

Regular Human Insulin

Dosage as individually required

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

Male or female patients with type 1 diabetes must present with the following:

• Established diagnosis of type 1 diabetes for more than 1 year.
• HbA1c values of not more than 10.5%.
• Three months on a stable insulin regimen that meets the current standard of care and that includes at least two daily insulin injections.
• Age: 18 to 70 years.
• Body Mass Index: 18 - 38 Kg/m2.

Exclusion Criteria

Patients presenting with any of the following will not be included in the study:

• Type 2 diabetes mellitus as determined by the investigator.
• History of frequent severe hypoglycemia within the prior six months.
• C-peptide > 1.0 ng/ml unless there is a documented history of ketoacidosis or a documented history of a positive anti GAD test.
• History of known hypersensitivity to any of the components in the study medication.
• History of severe or multiple allergies.
• Treatment with investigational diabetes drug in the last 3 months or treatment with any other investigational drug in the last 30 days before study entry.
• Current short-term treatment with systemic oral, injected, or inhaled corticosteroids. (inhaled corticosteroids may be allowed when the treatment is long-term).
• Progressive disease likely to prove fatal.
• History of malignancy within the past 5 years except for basal cell epithelioma.
• Known significant hepatic disease or serum AST or ALT values ≥ 3 X upper limit of normal or bilirubin levels ≥ 1.5 X upper limit of normal.
• Severe complications of diabetes mellitus including a history or finding of Stage III or IV diabetic retinopathy, proteinuria > 2+ by urine dipstick, serum creatinine of >1.8 mg/dl for males or >1.5 mg/dl for females, history of renal transplant, severe peripheral vascular disease which has resulted in an amputation, chronic foot ulcers claudication or absent pedal pulses.
• Known history of autonomic neuropathy.
• History of moderate to severe ketoacidosis within the 3 months preceding screening for the study.
• Current drug or alcohol abuse, or a history which in the opinion of the Investigator will impair patient safety or protocol compliance.
• Current significant cardiovascular, respiratory, gastrointestinal, hepatic, renal, neurological, psychiatric and/or hematological disease as evaluated by the Investigator.
• Blood donation within the last 30 days.
• A woman who is breast feeding.
• Pregnant women or women intending to become pregnant during the study.
• A sexually active woman of childbearing age not actively and consistently practicing birth control by using a medically accepted device or therapy.
• Abnormal ECG, safety lab or physical examination results which, in the opinion of the investigator, render the participation of the patient in the study to be inappropriate or unsafe.
• A history of lack of compliance with medical instructions, recent drug or alcohol abuse, or other reasons which, in the opinion of the investigator, render the participation of the patient in the study to be inappropriate or unsafe.
• Current significant diseases of the adrenal gland, pituitary gland or thyroid at the discretion of the investigator.
• Glomerular Filtration Rate < 40 ml/min.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Biodel

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

David C Klonoff, M.D., F.A.C.P.

Role: PRINCIPAL_INVESTIGATOR

Diabetes Research Institute

Related Links

http://www.biodel.com/

Type 1 Diabetes study

Other Identifiers

VIAject™-06J

Identifier Type: -

Identifier Source: org_study_id